Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank cut its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 28.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 122,207 shares of the biopharmaceutical company’s stock after selling 49,325 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.09% of Dynavax Technologies worth $1,708,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of DVAX. Vanguard Group Inc. raised its holdings in Dynavax Technologies by 3.1% during the third quarter. Vanguard Group Inc. now owns 9,146,891 shares of the biopharmaceutical company’s stock worth $135,100,000 after purchasing an additional 270,730 shares during the last quarter. Blair William & Co. IL raised its stake in shares of Dynavax Technologies by 0.6% during the 3rd quarter. Blair William & Co. IL now owns 2,470,191 shares of the biopharmaceutical company’s stock worth $36,485,000 after buying an additional 15,059 shares during the last quarter. Northern Trust Corp boosted its position in shares of Dynavax Technologies by 1.7% in the 3rd quarter. Northern Trust Corp now owns 1,446,728 shares of the biopharmaceutical company’s stock worth $21,368,000 after buying an additional 23,623 shares in the last quarter. Eventide Asset Management LLC grew its stake in Dynavax Technologies by 38.9% in the 3rd quarter. Eventide Asset Management LLC now owns 1,425,000 shares of the biopharmaceutical company’s stock valued at $21,047,000 after acquiring an additional 398,914 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Dynavax Technologies by 20.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,359,729 shares of the biopharmaceutical company’s stock valued at $20,083,000 after acquiring an additional 231,731 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Insiders Place Their Bets

In related news, CAO Justin Burgess sold 20,526 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $12.78, for a total value of $262,322.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.98% of the company’s stock.

Dynavax Technologies Stock Down 2.9 %

Shares of NASDAQ DVAX opened at $11.42 on Thursday. The firm has a market cap of $1.49 billion, a P/E ratio of -190.30 and a beta of 1.26. The company has a debt-to-equity ratio of 0.41, a quick ratio of 12.96 and a current ratio of 13.81. Dynavax Technologies Co. has a 1 year low of $10.06 and a 1 year high of $15.15. The firm’s 50 day moving average price is $12.28 and its 200 day moving average price is $13.23.

Wall Street Analysts Forecast Growth

DVAX has been the topic of several recent research reports. StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, April 17th. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 23rd. Finally, The Goldman Sachs Group initiated coverage on Dynavax Technologies in a research report on Thursday, February 1st. They set a “neutral” rating and a $20.00 price target for the company. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Dynavax Technologies has an average rating of “Moderate Buy” and an average price target of $25.00.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.